CPC-005 A Study to Evaluate Ustekinumab in Patients with Moderate to Severe Plaque Psoriasis: Abstract CPC-005 Table 1

Management of Moderate to Severe Plaque Psoriasis

cancer, arthritis, hypertension, heart disease, diabetes, and depression (Rapp 1999). In the last decade, a new understanding about the pathophysiology of psoriasis has resulted in the development of a new class of agents for these patients: targeted biologic therapy. These novel treatments target specific immunologic processes involved in the genesis of this disease, providing significant clin...

Phase 3 Clinical Trials Support STELARA® (ustekinumab) for the Treatment of Moderate to Severe Plaque Psoriasis

Ustekinumab for the treatment of moderate to severe psoriasis.

This paper presents a summary of the evidence review group (ERG) report into the clinical effectiveness and cost-effectiveness of ustekinumab for the treatment of moderate to severe psoriasis based upon a review of the manufacturer's submission to the National Institute for Health and Clinical Excellence (NICE) as part of the single technology appraisal (STA) process. The submission's main evid...

A histopathological study of smoking on free gingiva in patients with moderate to severe periodontitis

Introduction: Cigarette smoking has been recognized to be a risk factor for progression of periodontal disease . Due to less inflammation and bleeding in the presence of clinical signs of periodontal disease in smokers than in nonsmokers and given the conflicting results of studies on changes in the epithelium and gingival connective tissue by smoking, this study was performed to evaluate the t...

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: results of the randomized phase 3 CADMUS study.

BACKGROUND Safe and effective therapies are needed for pediatric patients with psoriasis. OBJECTIVE The purpose of this study was to evaluate ustekinumab in patients age 12 to 17 years who had moderate-to-severe psoriasis. METHODS Patients (n = 110) were randomly assigned to ustekinumab standard dosing (SD; 0.75 mg/kg [≤60 kg], 45 mg [>60-≤100 kg], and 90 mg [>100 kg]) or half-standard dosi...